These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19884554)

  • 21. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
    Fukumoto SI; Oizumi S; Harada M; Sukoh N; Nakano K; Fuke S; Sakakibara-Konishi J; Takamura K; Ito K; Fujita Y; Nishigaki Y; Harada T; Akie K; Kinoshita I; Amano T; Isobe H; Dosaka-Akita H; Nishimura M;
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):117-127. PubMed ID: 32564128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zhao H; Zhang H; Du Y; Gu X
    Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
    PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
    Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
    Metro G; Zheng Z; Fabi A; Schell M; Antoniani B; Mottolese M; Monteiro AN; Vici P; Lara Rivera S; Boulware D; Cognetti F; Bepler G
    Cancer Invest; 2010 Feb; 28(2):172-80. PubMed ID: 19968494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
    Holm B; Mellemgaard A; Skov T; Skov BG
    J Clin Oncol; 2009 Sep; 27(26):4254-9. PubMed ID: 19667277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
    Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR
    Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
    Rosell R; Scagliotti G; Danenberg KD; Lord RV; Bepler G; Novello S; Cooc J; Crinò L; Sánchez JJ; Taron M; Boni C; De Marinis F; Tonato M; Marangolo M; Gozzelino F; Di Costanzo F; Rinaldi M; Salonga D; Stephens C
    Oncogene; 2003 Jun; 22(23):3548-53. PubMed ID: 12789263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
    Akita H; Zheng Z; Takeda Y; Kim C; Kittaka N; Kobayashi S; Marubashi S; Takemasa I; Nagano H; Dono K; Nakamori S; Monden M; Mori M; Doki Y; Bepler G
    Oncogene; 2009 Aug; 28(32):2903-9. PubMed ID: 19543324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
    Muñoz-Montaño W; Muñiz-Hernández S; Avilés-Salas A; Catalán R; Lara-Mejía L; Samtani-Bassarmal S; Cardona AF; Mendoza-Desión J; Hernández-Cueto D; Maldonado A; Baay-Guzmán G; Huerta-Yepes S; Arrieta O
    BMC Cancer; 2021 Aug; 21(1):892. PubMed ID: 34353292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics and gemcitabine.
    Rosell R; Cobo M; Isla D; Camps C; Massuti B
    Ann Oncol; 2006 May; 17 Suppl 5():v13-16. PubMed ID: 16807441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z; Han B; Shen J; Gu A; Zhong H
    Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
    Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
    Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
    PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.